^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

VEGFA expression

i
Other names: VEGFA, Vascular endothelial growth factor A, VEGF, Vascular Endothelial Growth Factor A121, Vascular Endothelial Growth Factor A165, Vascular Endothelial Growth Factor, VEGF-A, MVCD1
Entrez ID:
Related biomarkers:
1d
Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9. (PubMed, Acta Pharmacol Sin)
We conclude that in addition to inhibiting angiogenesis, bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer. This study provides new insight into the mechanisms by which bevacizumab synergistically modulates ferroptosis and CD8+ T cell immune activity in liver cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • GZMB (Granzyme B) • SLC7A11 (Solute Carrier Family 7 Member 11) • HAT1 (Histone Acetyltransferase 1) • MIR143 (MicroRNA 143)
|
VEGFA expression
|
Avastin (bevacizumab)
2d
Spermidine Exerts Protective Effects in Random-Pattern Skin Flap Survival in Rats: Possible Involvement of Inflammatory Cytokines, Nitric Oxide, and VEGF. (PubMed, Aesthetic Plast Surg)
Spermidine could improve skin flaps survival, probably through the nitrergic system and inflammation pathways. This preclinical study provides level III evidence for the potential therapeutic effects of spermidine on SFS in rats, based on the analysis of animal models. Further studies are needed to confirm these findings in clinical settings.
Preclinical • Journal
|
VEGFA (Vascular endothelial growth factor A) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
VEGFA expression
2d
Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer. (PubMed, J Cannabis Res)
Finally, studies demonstrated that PC cells highly express CB1 and CB2 receptors and that cannabinoids are capable of inhibiting the release of exosomes and microvesicles related to cancer progression. Cannabinoids also have antiproliferative, anti-invasive, anti-fibroblastic, cell cycle arrest, and proapoptotic effects on PC cells.
Review • Journal
|
GPR55 (G Protein-Coupled Receptor 55)
|
VEGFA expression
3d
Down regulation of C1q tumor necrosis factor-related protein 6 is associated with increased risk of breast cancer. (PubMed, Arch Biochem Biophys)
Moreover, treatment of MCF-7 cells with recombinant CTRP6 protein reduced cellular viability and decreased IL-6, TNF-α and VEGF expression. In conclusion, these results provide new insights into the role of CTRP6 in BC pathogenesis and suggest its potential use as a novel diagnostic biomarker of BC.
Journal
|
IL6 (Interleukin 6)
|
VEGFA expression • IL6 expression
3d
Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF. (PubMed, Virchows Arch)
VEGF expression in macrophages was significantly higher in the good response group. In conclusion, this study enhances our understanding of immune-chemotherapy interactions in osteosarcoma and identifies potential biomarkers for targeted interventions.
Journal
|
IFNG (Interferon, gamma) • FAS (Fas cell surface death receptor) • CAT (Catalase)
|
IFNG expression • VEGFA expression
6d
E2F-mediated POLA2 upregulation is correlated with macrophage infiltration and poor prognosis in hepatocellular carcinoma. (PubMed, Transl Cancer Res)
POLA2 induced macrophage infiltration in the tumor microenvironment by upregulating the expression CSF1 and VEGFA expression. POLA2 is a novel diagnostic and prognostic biomarker of HCC with potential clinical value.
Journal
|
CSF1 (Colony stimulating factor 1) • E2F1 (E2F transcription factor 1) • POLA2 (DNA Polymerase Alpha 2)
|
VEGFA expression • CSF1 expression
6d
High STAT4 expression correlates with poor prognosis in acute myeloid leukemia and facilitates disease progression by upregulating VEGFA expression. (PubMed, Open Med (Wars))
VEGFA silencing counteracted the impacts of overexpressed STAT4 upon promoting viability and angiogenesis as well as repressing the apoptosis of AML cells. High STAT4 expression was correlated with poor prognosis of AML patients and facilitated disease progression via upregulating VEGFA expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • VEGFA (Vascular endothelial growth factor A) • BAX (BCL2-associated X protein) • STAT4 (Signal Transducer And Activator Of Transcription 4)
|
VEGFA expression
7d
Association of 18F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer. (PubMed, Auris Nasus Larynx)
Our findings suggest 18F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment.
Journal
|
HK2 (Hexokinase 2) • GLS1 (Glutaminase) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
VEGFA expression
8d
Diagnosis of Canine Tumours and the Value of Combined Detection of VEGF, P53, SF and NLRP3 for the Early Diagnosis of Canine Mammary Carcinoma. (PubMed, Animals (Basel))
By plotting the ROC curves, it was found that the results of combined tests were better than a single test and the combination of the four markers was the best for the early diagnosis. In conclusion, this can assist the clinical early diagnosis to a certain extent, and also provides some references and assistance for the development of tumor detection kits in clinical practice.
Journal
|
TP53 (Tumor protein P53) • VEGFA (Vascular endothelial growth factor A) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
VEGFA expression
8d
β-hydroxybutyrate Restrains Colitis-Associated Tumorigenesis by Inhibiting HIF-1α-Mediated Angiogenesis. (PubMed, Cancer Lett)
In summary, BHB carries out anti-angiogenic activity in CAC by regulating HIF-1α/VEGFA signaling. These findings emphasize the role of BHB in CAC and may provide novel perspectives for the prevention and treatment of colonic tumors.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression • VEGFA expression
10d
Differential expression of angiogenesis-related genes 'VEGF' and 'angiopoietin-1' in metastatic and EMAST-positive colorectal cancer patients. (PubMed, Sci Rep)
Yet, the generalization of in silico findings to EMAST+ colorectal cancer warrants future experimental investigations. In the end, this study proposes that the EMAST biomarker could serve as an additional perspective on CMS4 biology which is well-defined by activated angiogenesis and worse overall survival.
Journal • Metastases
|
VEGFA (Vascular endothelial growth factor A) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ANGPT2 (Angiopoietin 2) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • E2F1 (E2F transcription factor 1)
|
VEGFA expression • ANGPT2 expression
11d
CXCR2/Snail-1-Induced Epithelial-Mesenchymal Transition in the Formation and Progression of RCC with Inferior Vena Cava Tumour Thrombus. (PubMed, Arch Esp Urol)
Our findings suggest that CXCR2/Snail-1-induced EMT plays an important role in the formation and progression of RCC with inferior vena cava tumour thrombus. CXCR2/Snail-1 participates in the invasion and metastasis of RCC by regulating the expression of multiple signalling pathways and related genes. These results provide new insights and directions for the treatment of RCC.
Journal
|
MMP9 (Matrix metallopeptidase 9) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • SNAI1 (Snail Family Transcriptional Repressor 1)
|
VEGFA expression
13d
Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo. (PubMed, Asian Biomed (Res Rev News))
PGCsiRNA-VEGF promoted tissue apoptosis and destroyed the tissue structure. In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.
Preclinical • Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
VEGFA expression
13d
Clinical Implications of a Six-Protein Signature in Bone Metastasis of Renal Cell Carcinoma. (PubMed, J Cancer)
We treated one humeral metastases RCC patient with the anti-PDL1 antibody drug atezolizumab after examined the elevated expression of the 6 proteins in his nephrectomy tumor tissue, the tumor at the fracture site shrunk remarkably after four courses of treatment. These results altogether suggest a clinical implication of the 6-protein signature in RCC bone metastasis prognosis and response to immune-checkpoint inhibitor treatment.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PBRM1 (Polybromo 1)
|
VEGFA expression • CD8 negative
|
Tecentriq (atezolizumab)
14d
Downregulation of lncRNA MIR17HG reduced tumorigenicity and Treg-mediated immune escape of non-small-cell lung cancer cells through targeting the miR-17-5p/RUNX3 axis. (PubMed, J Biochem Mol Toxicol)
Additionally, we identified that runt- related transcription factor 3 (RUNX3) was a target of miR-17-5p, and sh-MIR17HG and miR-17-5p mimics downregulated RUNX3 expression. In conclusion, downregulation of MIR17HG suppresses tumorigenicity and Treg-mediated immune escape in NSCLC through downregulating the miR-17-5p/RUNX3 axis, indicating that this axis contains potential biomarkers for NSCLC.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TCF3 (Transcription Factor 3) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • RUNX3 (RUNX Family Transcription Factor 3) • IL4 (Interleukin 4) • MIR17 (MicroRNA 17) • MIR92A1 (MicroRNA 92a-1)
|
VEGFA expression
16d
Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. (PubMed, Chem Biol Drug Des)
In this review, we summarize the relationship between EGFR and VEGFR2 signal transduction in promoting cancer growth and how their kinase domain structures can affect the selectivity of an inhibitor as the basis for designing dual inhibitors. In addition, several recent studies on the development of dual EGFR and VEGFR2 inhibitors involving docking simulations were highlighted in this paper to provide some references such as pharmacophore features of inhibitors and key residues for further research, especially in computer-aided drug design.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
|
EGFR overexpression • KDR expression • VEGFA expression
21d
Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells. (PubMed, Anticancer Res)
CSDA is crucial for the proliferation of gastric cancer cells, and the inhibition of this protein could impede the advancement of gastric cancer.
Journal
|
HGF (Hepatocyte growth factor)
|
VEGFA expression
22d
Morphological and Molecular Biological Characteristics of Experimental Rat Glioblastoma Tissue Strains Induced by Different Carcinogenic Chemicals. (PubMed, Biomedicines)
GBM 101.8 is a reliable model for further investigation due to its similarity to high-grade human GBMs, while GBM 11-9-2 and GBM 14-4-5 correspond to Grade 2-3 gliomas.
Preclinical • Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MGMT (6-O-methylguanine-DNA methyltransferase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • SOX2
|
ABCB1 overexpression • HIF1A expression • VEGFA expression • MGMT expression • SOX2 expression
23d
Meroterpenoids from Marine Sponge Hyrtios sp. and Their Anticancer Activity against Human Colorectal Cancer Cells. (PubMed, Mar Drugs)
Furthermore, compounds 3 and 4 significantly suppressed the invasion of HCT-116 cells while also downregulating the expression of vascular endothelial growth factor receptor 1 (VEGFR-1) and vimentin proteins, which are key markers associated with angiogenesis and epithelial-mesenchymal transition (EMT). Our findings suggest that compounds 3 and 4 may exert their anti-invasive effects on tumor cells by inhibiting the expression of VEGFR-1 and impeding the process of EMT.
Journal
|
FLT1 (Fms-related tyrosine kinase 1) • VIM (Vimentin)
|
VEGFA expression • FLT1 expression
23d
Effect of salvia miltiorrhiza combined with roxadustat on wound healing of full-thickness skin defects in diabetic rats and its mechanism (PubMed, Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi)
At 14 d after injury, the protein expression level of EGFR in the wound tissue of rats in roxadustat+salvia miltiorrhiza group was significantly higher than the levels in the other 3 groups (with P values all 0.05). Roxadustat combined with salvia miltiorrhiza can promote the wound healing of full-thickness skin defects in diabetic rats by promoting blood vessel regeneration and reducing inflammatory response.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
EGFR expression • CD31 expression • HIF1A expression • VEGFA expression • IL6 expression • PCNA expression
|
Evrenzo (roxadustat)
26d
FOXO3a deregulation in uterine smooth muscle tumors. (PubMed, Clinics (Sao Paulo))
In summary, the outcomes of the present study suggest that the imbalance in FOXO3a within Uterine Smooth Muscle Tumors might arise from both protein phosphorylation and miRNA activity. FOXO3a could emerge as a promising therapeutic target for individuals with Unusual Leiomyomas and Leiomyosarcomas (ULM and LMS), offering novel directions for treatment strategies.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MIR155 (MicroRNA 155) • FOXO3 (Forkhead box O3) • MIR96 (MicroRNA 96) • Let-7c (MicroRNA Let-7c)
|
HER-2 expression • VEGFA expression
27d
Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells. (PubMed, Iran J Basic Med Sci)
This study aimed to explore the underlying mechanisms of histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to overcome resistance to tamoxifen in breast cancer cells...Finally, expression of vascular endothelial growth factor (VEGF), E-cadherin, Vimentin, phosphorylated phosphatidylinositol kinase (p-PI3k), phosphorylated protein kinase B (p-AKT), and phosphorylated mammalian target protein of rapamycin (p-mTOR) was evaluated by western blotting...However, HDAC inhibitor combined with PI3K inhibitor exerts more profound effects on the cancer cells as compared to HDAC inhibitor monotherapy. HDAC inhibitors inhibited the survival of breast cancer drug-resistant cells, invasion, migration, and angiogenesis by inhibiting the PI3k/Akt/mTOR signaling pathway.
Journal • Epigenetic controller
|
CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • VEGFA expression
|
tamoxifen • sirolimus • trichostatin A (VTR-297)
28d
Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF. (PubMed, Toxicol Appl Pharmacol)
More interestingly, ginsenoside CK co-treatment enhanced the expression of anti-angiogenic factor PF4, increased pericellular envelope, and promoted the normalization of vascular structure. In conclusion, ginsenoside CK improved the resistance of gefitinib by regulating the balance of angiogenic factors through down-regulating the HIF-1α/VEGF signaling pathway, providing a theoretical basis for improving the clinical efficacy of gefitinib and applying combined strategies to overcome drug resistance.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
HIF1A expression • VEGFA expression
|
gefitinib
29d
Potential imaging targets in primary head and neck squamous cell carcinoma and lymph node metastases. (PubMed, Am J Otolaryngol)
GPNMB expression is higher than EGFR in untreated HNSCC PT and corresponding LNM, while VEGF expression is comparable to EGFR. GPNMB is a promising target for fluorescent imaging in HNSCC.
Journal
|
EGFR (Epidermal growth factor receptor) • GPNMB (Glycoprotein Nmb)
|
EGFR expression • VEGFA expression • GPNMB expression
1m
Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient. (PubMed, J Ovarian Res)
Plasma VEGF-C holds immense promise as a prognostic marker and the nuclear staining of VEGF-C seems to have some significant implication in molecular carcinogenesis and is a novel finding that commands further robust scrutiny. We present a first such study that assesses a set of biomarkers for prognostic implications in clinical management of epithelial ovarian carcinomas in a pan-Indian (Asian) population.
Journal
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • VEGFC (Vascular Endothelial Growth Factor C) • NOS3 (Nitric oxide synthase 3)
|
VEGFA expression
1m
Hypoxia-associated markers in the prognosis of oral canine melanoma. (PubMed, Vet Pathol)
These findings reinforce the role of an hypoxic microenvironment in tumor progression and patient outcome in COMM, as previously established in several human and canine cancers. In addition, hypoxic markers may represent promising prognostic markers, highlighting opportunities for their use in therapeutic strategies for COMMs.
Journal • IO biomarker
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CA9 (Carbonic anhydrase 9) • CSPG4 (Chondroitin Sulfate Proteoglycan 4) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
HIF1A expression • VEGFA expression
1m
CircSNX6 promotes proliferation, metastasis, and angiogenesis in hepatocellular carcinoma via miR-383-5p/VEGFA signaling pathway. (PubMed, Sci Rep)
Subsequently, the stability of circRNA was evaluated through Ribonuclease R and actinomycin D treatment assays...Silencing circSNX6 also suppressed tumor formation and the metastasis of HCC cells in a mouse model. In summary, our findings suggest that circSNX6 promotes cell proliferation, metastasis, and angiogenesis in HCC by regulating the miR-383-5p/VEGFA pathway.
Journal
|
MIR383 (MicroRNA 383)
|
VEGFA overexpression • VEGFA expression
|
dactinomycin
1m
Evaluation of Some Prognostic Biomarkers in Human Papillomavirus-Related Multiphenotypic Sinonasal Carcinoma. (PubMed, Iran J Med Sci)
HMSC is strongly associated with HR-HPV. The expression of VEGF, EGFR, BAX, hTERT, and ProExTMC is associated with aggressive malignant behavior, poor survival, and poor prognosis, making them novel prognostic biomarkers for targeted therapeutics in HMSC.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase) • BAX (BCL2-associated X protein) • NFIB (Nuclear Factor I B) • TP63 (Tumor protein 63) • MYBL1 (MYB Proto-Oncogene Like 1)
|
EGFR expression • BAX expression • VEGFA expression
1m
Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. (PubMed, Mol Pharm)
In conclusion, [89Zr]Zr-Abe enables noninvasive analysis of VEGF expression, serving as a valuable tool for assessing the VEGF-targeted therapy effect. Additionally, all of the findings support the enhanced therapeutic efficacy and safety of [177Lu]Lu-Abe, making it a viable option for clinical practice in renal cancer.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD31 expression • VEGFA expression
1m
Dynamic contrast-enhanced magnetic resonance imaging in cervical cancer: correlation between quantitative parameters and molecular markers hypoxia-inducible factors-1-alpha, vascular endothelial growth factor, and Ki-67. (PubMed, Clin Radiol)
Our results suggest that DCE-MRI quantitative parameters could be potentially used as imaging markers for non-invasively detecting microenvironmental hypoxia, vascularity and proliferation in cervical cancer patients.
Journal • MRI
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression • VEGFA expression
1m
Expression and significance of pigment epithelium-derived factor and vascular endothelial growth factor in colorectal adenoma and cancer. (PubMed, World J Gastrointest Oncol)
It is possible that PEDF can be used as a new treatment and prevention target for CRC by upregulating the expression of PEDF while inhibiting the expression of VEGF.
Journal
|
VEGFA (Vascular endothelial growth factor A) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD31 expression • VEGFA expression
2ms
Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer. (PubMed, J Cancer Res Ther)
Overexpression of VEGF, PDGF-B, and HER2/neu might be possible prognostic biomarkers in GBC. Poor survival of VEGF and HER2/neu positive cases indicates the possibilities of using their blockers as therapeutic agents.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • VEGFA (Vascular endothelial growth factor A)
|
HER-2 overexpression • HER-2 expression • VEGFA overexpression • VEGFA expression
2ms
Journal
|
IFNG (Interferon, gamma) • IL10 (Interleukin 10) • VIM (Vimentin) • IL17A (Interleukin 17A)
|
VEGFA expression • VIM expression
2ms
Emodin ameliorates acute radiation proctitis in mice by regulating AKT/MAPK/NF-κB/VEGF pathways. (PubMed, Int Immunopharmacol)
These results suggest that emodin attenuates ARP in mice, and the underlying mechanism might involve inhibition of the AKT/ERK/NF-κB/VEGF pathways and the induction of apoptosis mediated by JNK and p38.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • AQP1 (Aquaporin 1)
|
BCL2 expression • BAX expression • VEGFA expression
|
MK-2206
2ms
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. (PubMed, Cancer Immunol Immunother)
Our preclinical studies collectively offer substantiation that CD47 holds promise as a prospective target for gastric cancer, while also highlighting the potential of anti-angiogenic therapy to enhance tumor responsiveness to anti-CD47 immunotherapy.
Journal • IO biomarker
|
CD47 (CD47 Molecule) • FLT1 (Fms-related tyrosine kinase 1) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression • VEGFA expression
2ms
Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines. (PubMed, Med Oncol)
α1-AR inhibition reversed cellular proliferation and VEGF-A secretion by MCF-7 cells while α2-AR inhibition reversed the proliferation of MCF-7 and MDA MB-231 cells and VEGF-C secretion by MCF-7 cells. Taken together, breast cancer pathogenesis may be influenced by distinct α-AR-mediated signaling mechanisms on angiogenesis and lymphangiogenesis that are dependent on estrogen receptor status.
Preclinical • Journal
|
ER (Estrogen receptor) • VEGFC (Vascular Endothelial Growth Factor C)
|
ER positive • VEGFA expression
2ms
FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation. (PubMed, Cell Death Discov)
In addition, our data confirm that there are positive correlations among FBXO22, HIF-1α, and VEGFA expression, and there is a negative correlation between FBXO22 and VHL protein expression in glioma patients. Our study strongly indicates that FBXO22 is a promising diagnostic marker and therapeutic target for glioma patients.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor)
|
HIF1A expression • VEGFA expression
2ms
Linoleic acid exhibits anti-proliferative and anti-invasive activities in endometrial cancer cells and a transgenic model of endometrial cancer. (PubMed, Cancer Biol Ther)
Furthermore, treatment of Lkb1fl/flp53fl/fl transgenic mice with linoleic acid for four weeks significantly reduced the growth of endometrial tumors and decreased the expression of VEGF, vimentin, Ki67, and cyclin D1 in tumor tissues. Our findings demonstrate that linoleic acid exhibits anti-proliferative and anti-invasive activities in endometrial cancer cell lines and the Lkb1fl/flp53fl/fl mouse model of endometrial cancer, thus providing a pre-clinical basis for future dietary interventions with linoleic acid in endometrial cancer.
Journal
|
CCND1 (Cyclin D1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CCND1 expression • VEGFA expression • VIM expression
2ms
Deciphering the Mechanism of Siwu Decoction Inhibiting Liver Metastasis by Integrating Network Pharmacology and In Vivo Experimental Validation. (PubMed, Integr Cancer Ther)
This study clarified the active ingredients of SWD, the therapeutic targets of LM and potential molecular mechanisms. SWD may protect against LM through suppressing HIF-1/VEGF pathway.
Preclinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD31 expression • HIF1A expression • VEGFA expression
2ms
Zeolitic imidazolate framework-90 loaded with methylprednisolone sodium succinate effectively reduces hypertrophic scar in vivo. (PubMed, Nanoscale)
This work provides evidence of effective intervention in the formation of an HS and the therapeutic effectiveness of MPSS@ZIF-90 with short treatment periods in vivo. It suggests that MPSS@ZIF-90 can be used as a biomedical option in the treatment of skin wounds and may reveal the potential molecular basis for promising future antifibrotic agents against scarring.
Preclinical • Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
VEGFA expression
2ms
SERPINB5 promotes colorectal cancer invasion and migration by promoting EMT and angiogenesis via the TNF-α/NF-κB pathway. (PubMed, Int Immunopharmacol)
In summary, our findings revealed that high SERPINB5 expression correlated with poor progression-free survival in CRC patients. Moreover, SERPINB5 could induce EMT and angiogenesis by activating the TNF-α/NF-κB pathway, thereby promoting the invasion and migration of CRC cells.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9)
|
CDH1 expression • VEGFA expression
2ms
Doxazosin inhibits vasculogenic mimicry in human non‑small cell lung cancer through inhibition of the VEGF‑A/VE‑cadherin/mTOR/MMP pathway. (PubMed, Oncol Lett)
In conclusion, the present study demonstrated that doxazosin displayed anti-VM activity in an NSCLC cell model through the downregulation of VEGF-A and VE-cadherin levels, and the suppression of signaling pathways related to the receptor tyrosine kinase, EphA2, protein kinases, AKT and mTOR, and proteases, MMP-2 and MMP-9. These results support the add-on anti-VM effect of doxazosin as a potential agent against NSCLC.
Journal • IO biomarker
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • CDH5 (Cadherin 5)
|
CDH1 expression • VEGFA expression